Home/Filings/4/0001437749-25-035821
4//SEC Filing

Schoenberg Mark 4

Accession 0001437749-25-035821

CIK 0001668243other

Filed

Nov 19, 7:00 PM ET

Accepted

Nov 20, 1:42 PM ET

Size

4.9 KB

Accession

0001437749-25-035821

Insider Transaction Report

Form 4
Period: 2025-11-19
Schoenberg Mark
Chief Medical Officer
Transactions
  • Sale

    Ordinary Shares

    2025-11-19$25.00/sh10,000$250,000139,025 total
Footnotes (2)
  • [F1]Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). Adoption date of referenced 10b5-1(c) plan is: 08-15-2025.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 and $25.02. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Issuer

UroGen Pharma Ltd.

CIK 0001668243

Entity typeother

Related Parties

1
  • filerCIK 0001763581

Filing Metadata

Form type
4
Filed
Nov 19, 7:00 PM ET
Accepted
Nov 20, 1:42 PM ET
Size
4.9 KB